Literature DB >> 16460997

Comparison of the grade evaluated by "Liver damage" of Liver Cancer Study Group of Japan and Child-Pugh classification in patients with hepatocellular carcinoma.

Katsuhisa Omagari1, Kazuo Ohba, Yoshiko Kadokawa, Hiroaki Hazama, Jun-Ichi Masuda, Hideki Kinoshita, Isao Matsuo, Ken Ohnita, Yohei Mizuta, Kenji Hayashida, Shigeru Kohno.   

Abstract

BACKGROUND: The "Liver damage" classification proposed by the Liver Cancer Study Group of Japan and Child-Pugh classification are both useful classifications for hepatic function. However, the factors responsible for the difference between the two classifications have not been fully investigated.
METHODS: The medical records of 594 admissions of 220 patients with hepatocellular carcinoma (HCC) were retrospectively analyzed for encephalopathy, ascites, serum bilirubin and albumin, plasma retention rate (%) at 15min after injection of 0.5mg/kg of indocyanine green (ICG R15), and prothrombin time.
RESULTS: Of 594 admissions, ICG R15 was tested in 337 (56.7%). The Child-Pugh classification was evaluated in all 594 admissions, but the "Liver damage" could be evaluated in 510 (85.9%) due to the lack of ICG R15 results. Of the 594 admissions, 372 (62.6%), 162 (27.3%), and 60 (10.1%) were Child-Pugh grade A, B, and C, respectively. Of the 510 admissions, 219 (42.9%), 202 (39.6%), and 89 (17.5%) were "Liver damage" grade A, B, and C, respectively. The grade of "Liver damage" was similar to that of Child-Pugh classification in 369 (72.4%), under-evaluated in 138 (27.1%), and over-evaluated in 3 (0.6%). The Child-Pugh classification was statistically a better classification for predicting outcome than "Liver damage", but the "Liver damage" had better stratification ability than Child-Pugh classification in patients with relatively good liver function.
CONCLUSIONS: Although the "Liver damage" could not be evaluated in some cases due to the lack of ICG R15 results, this classification system is useful in the evaluation and prediction of outcome of patients with early-stage liver diseases.

Entities:  

Year:  2006        PMID: 16460997     DOI: 10.1016/j.hepres.2005.05.010

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  10 in total

1.  Albumin-Bilirubin Grade and Hepatocellular Carcinoma Treatment Algorithm.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2017-03-09       Impact factor: 11.740

2.  Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications.

Authors:  Atsushi Hiraoka; Takashi Kumada; Masatoshi Kudo; Masashi Hirooka; Kunihiko Tsuji; Ei Itobayashi; Kazuya Kariyama; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Toshifumi Tada; Hidenori Toyoda; Kazuhiro Nouso; Kouji Joko; Hideki Kawasaki; Yoichi Hiasa; Kojiro Michitaka
Journal:  Liver Cancer       Date:  2017-03-09       Impact factor: 11.740

Review 3.  Laparoscopic liver resection for the patients with hepatocellular carcinoma and chronic liver disease.

Authors:  Zenichi Morise
Journal:  Transl Gastroenterol Hepatol       Date:  2018-07-16

4.  Is Portal Vein Embolization Followed by Hepatectomy for Hepatocellular Carcinoma Justified in Patients with Impaired Liver Function?

Authors:  Katsunori Imai; Yo-Ichi Yamashita; Yosuke Nakao; Takashi Matsumoto; Shotaro Kinoshita; Toshihiko Yusa; Yuki Kitano; Takayoshi Kaida; Hiromitsu Hayashi; Hideo Baba
Journal:  Ann Surg Oncol       Date:  2020-08-01       Impact factor: 5.344

Review 5.  Preoperative liver function assessments to estimate the prognosis and safety of liver resections.

Authors:  Toru Mizuguchi; Masaki Kawamoto; Makoto Meguro; Thomas T Hui; Koichi Hirata
Journal:  Surg Today       Date:  2013-03-09       Impact factor: 2.549

6.  Comparative study of the Japan Integrated Stage (JIS) and modified JIS score as a predictor of survival after hepatectomy for hepatocellular carcinoma.

Authors:  Kai-Zhong Luo; Toshiyuki Itamoto; Hironobu Amano; Akihiko Oshita; Yuichiro Ushitora; Yoshisato Tanimoto; Hideki Ohdan; Hirotaka Tashiro; Toshimasa Asahara
Journal:  J Gastroenterol       Date:  2008-07-01       Impact factor: 7.527

Review 7.  Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients.

Authors:  Atsushi Hiraoka; Takashi Kumada; Kojiro Michitaka; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2018-11-29       Impact factor: 11.740

8.  "Incidentaloma" of the liver: management of a diagnostic and therapeutic dilemma.

Authors:  Denis Ehrl; Katharina Rothaug; Peter Herzog; Bernhard Hofer; Horst-Günter Rau
Journal:  HPB Surg       Date:  2012-08-08

9.  Overview and clinical significance of multiple mutations in individual genes in hepatocellular carcinoma.

Authors:  Taisuke Imamura; Yukiyasu Okamura; Keiichi Ohshima; Katsuhiko Uesaka; Teiichi Sugiura; Takaaki Ito; Yusuke Yamamoto; Ryo Ashida; Katsuhisa Ohgi; Shimpei Otsuka; Sumiko Ohnami; Takeshi Nagashima; Keiichi Hatakeyama; Takashi Sugino; Kenichi Urakami; Yasuto Akiyama; Ken Yamaguchi
Journal:  BMC Cancer       Date:  2022-10-05       Impact factor: 4.638

Review 10.  Prognostic value of the albumin-bilirubin grade in patients with hepatocellular carcinoma and other liver diseases.

Authors:  Dayun Feng; Mengmeng Wang; Jie Hu; Songlun Li; Shoujie Zhao; Huichen Li; Lei Liu
Journal:  Ann Transl Med       Date:  2020-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.